"Dwarf" estrogen receptor in breast cancer and resistance to tamoxifen

Journal of Clinical Oncology

Volumn 27, Issue 21, 2009, Pages 3413-3415

  Fowler, Amy M ^a   Santen, Richard J ^b   Allred, D Craig ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA36; ESTROGEN RECEPTOR ALPHA66; TAMOXIFEN; UNCLASSIFIED DRUG; ESR1 PROTEIN, HUMAN; ESTROGEN RECEPTOR;

BREAST CANCER; CANCER SURVIVAL; DRUG RESPONSE; EDITORIAL; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR INTRINSIC ACTIVITY; BIOCHEMISTRY; BREAST TUMOR; DRUG RESISTANCE; ECONOMICS; FEMALE; GENETICS; MALE; METABOLISM; TUMOR CELL CULTURE;

BIOCHEMICAL PROCESSES; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MALE; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 70249091820     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.21.8776     Document Type: Editorial

References (18)

1. Shi L, Dong B, Li Z, et al: Expression of ER-α36, a novel variation of estrogen receptor α, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 27:3423-3429, 2009
2. Wang Z, Zhang X, Shen P, et al: A variant of estrogen receptor-α hERα36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A 103:9063-9068, 2006
3. Lee LM, Cao J, Deng H, et al: ER-α 36, a novel variant of ER-α , is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res 28:479-483, 2008
4. Razzak AR, Lin NU, Winer EP: Heterogeneity of breast cancer and implications of adjuvant chemotherapy. Breast Cancer 15:31-34, 2008
5. Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005
6. Coates AS, Keshaviah A, Thurlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 25:486-492, 2007
7. Flouriot G, Brand H, Denger S, et al: Identification of a new isoform of the human estrogen receptor-α (hER-α ) that is encoded by distinct transcripts and that is able to repress hER-α activation function 1. Embo J 19:4688-4700, 2000
8. Ogawa S, Inoue S, Watanabe T, et al: Molecular cloning and characterization of human estrogen receptor βcx: A potential inhibitor of estrogen action in human. Nucleic Acids Res 26:3505-3512, 1998
9. Condon JC, Hardy DB, Kovaric K, et al: Up-regulation of the progesterone receptor (PR)-C isoform in laboring myometrium by activation of nuclear factor-κB may contribute to the onset of labor through inhibition of PR function. Mol Endocrinol 20:764-775, 2006
10. Oakley RH, Jewell CM, Yudt MR, et al: The dominant negative activity of the human glucocorticoid receptor β isoform. Specificity and mechanisms of action. J Biol Chem 274:27857-27866, 1999
11. Acconcia F, Ascenzi P, Bocedi A, et al: Palmitoylation-dependent estrogen receptor α membrane localization: Regulation by 17β-estradiol. Mol Biol Cell 16:231-237, 2005
12. Levin ER, Pietras RJ: Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat 108:351-361, 2008
13. Boonyaratanakornkit V, Edwards DP: Receptor mechanisms mediating non-genomic actions of sex steroids. Semin Reprod Med 25:139-153, 2007
14. Moriarty K, Kim KH, Bender JR: Minireview: Estrogen receptor-mediated rapid signaling. Endocrinology 147:5557-5563, 2006
15. Song RX, Santen RJ: Membrane initiated estrogen signaling in breast cancer. Biol Reprod 75:9-16, 2006
16. Harrington WR, Kim SH, Funk CC, et al: Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol Endocrinol 20:491-502, 2006
17. Zujewski JA, Kamin L: Trial assessing individualized options for treatment for breast cancer: The TAILORx trial. Future Oncol 4:603-610, 2008
18. Cardoso F, Van't Veer L, Rutgers E, et al: Clinical application of the 70-gene profile: The MINDACT trial. J Clin Oncol 26:729-735, 2008